Compare DHX & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DHX | IPHA |
|---|---|---|
| Founded | 1991 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.0M | 165.3M |
| IPO Year | 2007 | 2014 |
| Metric | DHX | IPHA |
|---|---|---|
| Price | $4.89 | $1.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $6.25 | $5.75 |
| AVG Volume (30 Days) | ★ 286.9K | 32.5K |
| Earning Date | 05-05-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $127,826,000.00 | N/A |
| Revenue This Year | N/A | $180.36 |
| Revenue Next Year | $3.52 | N/A |
| P/E Ratio | $49.90 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.44 | $1.18 |
| 52 Week High | $5.19 | $2.71 |
| Indicator | DHX | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 63.21 | 43.86 |
| Support Level | $3.80 | $1.67 |
| Resistance Level | N/A | $2.66 |
| Average True Range (ATR) | 0.28 | 0.11 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 77.34 | 18.24 |
DHI Group Inc is a provider of software products, online tools, and services that deliver career marketplaces to candidates and employers in the United States. The company operates through two reportable segments: ClearanceJobs and Dice. Its brands enable recruiters and hiring managers to search, match, and connect with skilled technologists, particularly in technology and active government security clearance, while professionals find job opportunities, job advice, and personalized data. ClearanceJobs connects security-cleared professionals with employers in a secure environment and supports engagement through messaging and live video. Dice, which generates maximum revenue, is a destination for technology and engineering talent, offering job postings across a range of technology roles.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.